申请人:Eli Lilly and Company
公开号:US08048884B2
公开(公告)日:2011-11-01
The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine:
where A is —C(H)═ or —N═; m is 0, 1 or 2; R1 is optionally substituted phenyl, optionally substituted pyrazol-4-yl; optionally substituted imidazolyl, optionally substituted pyridyl, or thienyl; R2 is hydrogen or methyl; and R3 and R4 are as defined herein.
本发明提供了式I的选择性5-HT7受体拮抗剂化合物及其在治疗偏头痛中的应用:其中A为—C(H)═或—N═; m为0、1或2; R1为可选取代的苯基、可选取代的吡唑-4-基; 可选取代的咪唑基、可选取代的吡啶基或噻吩基; R2为氢或甲基; R3和R4如本文所定义。